Synergistic therapy for breast cancer with miRNA and lipid nanoparticles
December 2016
Zhejiang University, Hangzhou, China
Cancer stem cells are a major obstacle in the treatment of breast cancer due to, among other things, their drug resistance capabilities. However, microRNA-200c has been described to reduce the expression of class III beta-tubulin, which recovers sensitivity to microtubule-targeting drugs. Here, a combination of microRNA-200c and paclitaxel mediated by lipid nanoparticles is used to target breast cancer stem cells in mammospheres generated with human breast cancer cells. The results show that the lipid nanoparticles protected microRNA-200c from degradation and had higher cellular uptake efficiency than other methods. Furthermore, the microRNA-200c could be efficiently released from the lipid complex inside the cell. Finally, the transfection of the microRNA-200c-lipid complex into breast cancer stem cells induced downregulation of class III beta-tubulin and enhanced paclitaxel-mediated cytotoxicity of breast cancer stem cells. Overall, the researchers develop a new drug release strategy to deliver microRNA-200c in target-specific areas that, when combined with chemotherapy, can induce cell death of breast cancer stem cells.
MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
Fuqiang Hu
Added on: 10-30-2021
[1] https://www.dovepress.com/microrna-200c-delivered-by-solid-lipid-nanoparticles-enhances-the-effe-peer-reviewed-fulltext-article-IJN[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
